Entrada Therapeutics, Inc.
NASDAQ:TRDA
5.28 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Entrada Therapeutics, Inc. | 
| Symbool | TRDA | 
| Munteenheid | USD | 
| Prijs | 5.28 | 
| Beurswaarde    |  200,835,782 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 4.93 - 21.79 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. Dipal Doshi | 
| Website | https://www.entradatx.com | 
An error occurred while fetching data.
Over Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)







